Taking people in United StatesPhase 2

Tests approved cancer drugs chosen by a tumor's gene change in advanced cancer

Studies existing drugs aimed at tumor gene changes in advanced cancer.

Plain-language title generated from the registry record
Registry title: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Key facts

Where: ‘Ewa Beach, Albuquerque, Allentown, Altamonte Springs, Ann Arbor, Atlanta, Auburn, Augusta, Aventura, Belfast, Berkeley, Bethlehem, Biddeford, Birmingham, Bismarck, Bluffton, Bonita Springs, Bonney Lake, Bradenton, Brandon, Brewer, Bridgeport, Brunswick, Burlington, Cape Coral, Cedar City, Chapel Hill, Charlotte, Chicago, Cincinnati, Clearwater, Concord, Coral Gables, Deerfield Beach, Detroit, East Stroudsburg, Fairfax, Fargo, Federal Way, Flint, Fort Lauderdale, Fort Myers, Gainesville, Germantown, Gig Harbor, Grafton, Grand Rapids, Green Bay, Hartford, Hazleton, Hilton Head Island, Honolulu, Houston, Indianapolis, Kennebunk, Kenosha, Kettering, Kittery, Lake Success, Lansing, Largo, Las Cruces, Lecanto, Livonia, Los Angeles, Manchester, Marinette, Meriden, Miami, Milwaukee, Mount Kisco, Naples, Nashville, New Britain, New Hyde Park, New York, Norway, Norwich, Oakland, Ocala, Olympia, Omaha, Orange City, Orlando, Oshkosh, Palo Alto, Philadelphia, Phoenix, Plantation, Pontiac, Port Charlotte, Portland, Portsmouth, Puyallup, Racine, Rego Park, Rio Rancho, Rockport, Roseville, Sacramento, Saginaw, Salt Lake City, San Francisco, San Jose, San Leandro, Sanford, Santa Barbara, Santa Clara, Santa Cruz, Sarasota, Savannah, Scarborough, Seattle, Sheboygan, Sioux Falls, Sleepy Hollow, South Portland, St. George, St. Petersburg, Summit, Sunnyvale, Tacoma, Tampa, Tavares, The Villages, Topsham, Torrington, Traverse City, Trinity, Two Rivers, Vallejo, Venice, Walnut Creek, Warren, Wauwatosa, Wells, West Chester, Willimantic, Winter Park, and York Village, United StatesSee the 170 sites
Phase: Phase 2

Where in United States

The Queen's Medical Center - West Oahu‘Ewa Beach, United StatesTaking people
Lovelace Medical Center-Saint Joseph SquareAlbuquerque, United StatesTaking people
Presbyterian Kaseman HospitalAlbuquerque, United StatesTaking people
The University of New Mexico Comprehensive Cancer CenterAlbuquerque, United StatesTaking people
Lehigh Valley Hospital-Cedar CrestAllentown, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteAltamonte Springs, United StatesNo longer taking part
Trinity Health Ann Arbor HospitalAnn Arbor, United StatesTaking people
University of MichiganAnn Arbor, United StatesNo longer taking part
Cancer Treatment Centers of America - AtlantaAtlanta, United StatesTaking people
Emory University/Winship Cancer InstituteAtlanta, United StatesTaking people
Sutter AuburnAuburn, United StatesTaking people
Harold Alfond Center for Cancer CareAugusta, United StatesTaking people
Jackson Laboratory - Maine Cancer Genomics InitiativeAugusta, United StatesTaking people
University of Miami/Sylvester Cancer Institute - AventuraAventura, United StatesTaking people
Waldo County General HospitalBelfast, United StatesTaking people
Sutter Alta BatesBerkeley, United StatesTaking people
Lehigh Valley Hospital - MuhlenbergBethlehem, United StatesTaking people
SMHC Cancer Care and Blood Disorders -BiddefordBiddeford, United StatesTaking people
University of Alabama at Birmingham, Comprehensive Cancer CenterBirmingham, United StatesTaking people
Sanford Health- BismarckBismarck, United StatesTaking people
SC Cancer Specialists at St. Joseph's/Candler BlufftonBluffton, United StatesTaking people
St. Joseph's/Candler SmithBluffton, United StatesTaking people
Summit Cancer Care at St. Josph's/Candler BlufftonBluffton, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstituteBonita Springs, United StatesNo longer taking part
Northwest Medical SpecialtiesBonney Lake, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstituteBradenton, United StatesNo longer taking part
Florida Cancer Specialists North / Sarah Cannon Research InstituteBrandon, United StatesNo longer taking part
Northern Light Cancer CareBrewer, United StatesTaking people
Raish Peavey Haskell Children's Cancer and Treatment CenterBrewer, United StatesTaking people
Saint Vincent's Medical Center (SVMC)Bridgeport, United StatesTaking people
MaineHealth Cancer Care -BrunswickBrunswick, United StatesTaking people
Aurora Cancer Care - BurlingtonBurlington, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstituteCape Coral, United StatesNo longer taking part
Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer CenterCedar City, United StatesTaking people
Lineberger Comprehensive Cancer CenterChapel Hill, United StatesTaking people
Atrium Health's Levine Cancer InstituteCharlotte, United StatesTaking people
Cancer Treatment Centers of America-ChicagoChicago, United StatesTaking people
University of Cincinnati Medical CenterCincinnati, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteClearwater, United StatesNo longer taking part
NH Oncology - Hematology, PAConcord, United StatesTaking people
University of Miami/Sylvester Cancer Institute - LennarCoral Gables, United StatesTaking people
University of Miami/Sylvester Cancer Institute - Deerfield BeachDeerfield Beach, United StatesTaking people
Henry Ford Health Saint John HospitalDetroit, United StatesTaking people
Pocono Medical CenterEast Stroudsburg, United StatesTaking people
Inova Schar Cancer InstituteFairfax, United StatesTaking people
Sanford Health- FargoFargo, United StatesTaking people
Northwest Medical SpecialtiesFederal Way, United StatesTaking people
Genesys Hurley Cancer InstituteFlint, United StatesTaking people
Holy Cross HospitalFort Lauderdale, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstituteFort Myers, United StatesNo longer taking part
University of Florida HealthGainesville, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteGainesville, United StatesNo longer taking part
Aurora Health Care Germantown Health CenterGermantown, United StatesTaking people
Northwest Medical SpecialtiesGig Harbor, United StatesTaking people
Aurora Cancer Care-GraftonGrafton, United StatesTaking people
Cancer Research Consortium of West MichiganGrand Rapids, United StatesTaking people
Aurora BayCare Medical CenterGreen Bay, United StatesTaking people
Hartford HospitalHartford, United StatesTaking people
Lehigh Valley Hospital-HazletonHazleton, United StatesTaking people
South Carolina Cancer SpecialistsHilton Head Island, United StatesTaking people
The Queen's Medical Center - KuakiniHonolulu, United StatesTaking people
The Queen's Medical Center - POB IHonolulu, United StatesTaking people
The Queen's Medical Center - PunchbowlHonolulu, United StatesTaking people
The University of Texas MD Anderson Cancer CenterHouston, United StatesTaking people
Community Health Network (The University of Texas MD Anderson Cancer Center)Indianapolis, United StatesTaking people
New England Cancer SpecialistKennebunk, United StatesTaking people
Aurora Cancer Care-Kenosha SouthKenosha, United StatesTaking people
Kettering HealthKettering, United StatesTaking people
York Hopsital Oncology & Infusion Care in KitteryKittery, United StatesTaking people
Northwell Health Monter Cancer CenterLake Success, United StatesTaking people
University of Michigan Health - Sparrow LansingLansing, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteLargo, United StatesNo longer taking part
Memorial Medical CenterLas Cruces, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteLecanto, United StatesNo longer taking part
Trinity Health Livonia HospitalLivonia, United StatesTaking people
The Angeles Clinic and Research Institute- A Cedars-Sinai AffiliateLos Angeles, United StatesTaking people
Solinsky Center for Cancer CareManchester, United StatesTaking people
Aurora Bay Area Medical CenterMarinette, United StatesTaking people
Midstate Medical Center (MSMC)Meriden, United StatesTaking people
University of Miami - Sylvester Comprehensive Cancer CenterMiami, United StatesTaking people
University of Miami/Sylvester Cancer Institute - Alex's PlaceMiami, United StatesTaking people
University of Miami/Sylvester Cancer Institute - Griffin Cancer Research BuildingMiami, United StatesTaking people
University of Miami/Sylvester Cancer Institute - KendallMiami, United StatesTaking people
University of Miami/Sylvester Cancer Institute - Sole MiaMiami, United StatesTaking people
Aurora Cancer Care-MilwaukeeMilwaukee, United StatesTaking people
Aurora Sinai Medical CenterMilwaukee, United StatesTaking people
Aurora St. Luke's Medical CenterMilwaukee, United StatesTaking people
Aurora West Allis Medical CenterMilwaukee, United StatesTaking people
Northern Westchester HospitalMount Kisco, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstituteNaples, United StatesNo longer taking part
Tennessee Oncology-Nashville/Sarah Cannon Research InstituteNashville, United StatesTaking people
The Hospital of Central Connecticut (HOCC) Cancer CenterNew Britain, United StatesTaking people
Cohen Children's Medical CenterNew Hyde Park, United StatesTaking people
Manhattan Eye Ear and Throat HospitalNew York, United StatesTaking people
Staten Island University HospitalNew York, United StatesTaking people
Stephens Memorial HospitalNorway, United StatesTaking people
William W. Backus HospitalNorwich, United StatesTaking people
Kaiser Permanente Oakland Medical CenterOakland, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteOcala, United StatesNo longer taking part
Northwest Medical SpecialtiesOlympia, United StatesTaking people
University of Nebraska Medical CenterOmaha, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteOrange City, United StatesNo longer taking part
Florida Cancer Specialists North / Sarah Cannon Research InstituteOrlando, United StatesNo longer taking part
Vince Lombardi Cancer Clinic - OshkoshOshkosh, United StatesTaking people
Sutter Palo Alto Medical Foundation: Palo AltoPalo Alto, United StatesTaking people
Fox Chase Cancer CenterPhiladelphia, United StatesTaking people
Cancer Treatment Centers of America-PhoenixPhoenix, United StatesTaking people
University of Miami/Sylvester Cancer Institute - PlantationPlantation, United StatesTaking people
Trinity Health Oakland HospitalPontiac, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstitutePort Charlotte, United StatesNo longer taking part
Providence Health & ServicesPortland, United StatesTaking people
New England Cancer SpecialistPortsmouth, United StatesTaking people
Northwest Medical SpecialtiesPuyallup, United StatesTaking people
Aurora Cancer Care-RacineRacine, United StatesTaking people
Queens Cancer CenterRego Park, United StatesTaking people
Presbyterian Rust Medical CenterRio Rancho, United StatesTaking people
Penobscot Bay Medical CenterRockport, United StatesTaking people
Kaiser Permanente Roseville Medical CenterRoseville, United StatesTaking people
Sutter RosevilleRoseville, United StatesTaking people
Kaiser Permanente Sacramento Medical CenterSacramento, United StatesTaking people
Sutter SacramentoSacramento, United StatesTaking people
MyMichigan Medical Center SaginawSaginaw, United StatesTaking people
Intermountain HealthcareSalt Lake City, United StatesTaking people
California Pacific Medical Center Research InstituteSan Francisco, United StatesTaking people
Kaiser Permanente - South San Francisco Medical CenterSan Francisco, United StatesTaking people
Kaiser Permanente San Francisco Medical CenterSan Francisco, United StatesTaking people
Sutter Cancer Research ConsortiumSan Francisco, United StatesTaking people
Kaiser Permanente - San Jose Medical CenterSan Jose, United StatesTaking people
Kaiser Permanente - San Leandro Medical CenterSan Leandro, United StatesTaking people
SMHC Cancer Care and Blood Disorders -SandfordSanford, United StatesTaking people
Sutter Sansum ClinicSanta Barbara, United StatesTaking people
Kaiser Permanente Santa Clara Medical CenterSanta Clara, United StatesTaking people
Sutter Palo Alto Medical Foundation: FremontSanta Cruz, United StatesTaking people
Sutter Palo Alto Medical Foundation: Santa CruzSanta Cruz, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstituteSarasota, United StatesNo longer taking part
Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research PavilionSavannah, United StatesTaking people
Lewis Cancer & Research PavilionSavannah, United StatesTaking people
Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma InstituteSavannah, United StatesTaking people
Summit Cancer CareSavannah, United StatesTaking people
Maine Children's Cancer ProgramScarborough, United StatesTaking people
Maine Medical Partner's Women's HealthScarborough, United StatesTaking people
New England Cancer SpecialistScarborough, United StatesTaking people
Swedish Cancer InstituteSeattle, United StatesTaking people
Vince Lombardi Cancer CenterSheboygan, United StatesTaking people
Sanford Cancer Center Oncology Clinic and PharmacySioux Falls, United StatesTaking people
Phelps HospitalSleepy Hollow, United StatesTaking people
MaineHealth Cancer Care -South PortlandSouth Portland, United StatesTaking people
Dixie Regional Medical Center-River Road CampusSt. George, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteSt. Petersburg, United StatesNo longer taking part
Aurora Medical Center in SummitSummit, United StatesTaking people
Sutter Palo Alto Medical Foundation: SunnyvaleSunnyvale, United StatesTaking people
Northwest Medical SpecialtiesTacoma, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteTampa, United StatesNo longer taking part
Florida Cancer Specialists North / Sarah Cannon Research InstituteTavares, United StatesNo longer taking part
Florida Cancer Specialists North / Sarah Cannon Research InstituteThe Villages, United StatesNo longer taking part
New England Cancer SpecialistTopsham, United StatesTaking people
Charlotte HungerfordTorrington, United StatesTaking people
Michigan Cancer Research ConsortiumTraverse City, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteTrinity, United StatesNo longer taking part
Vince Lombardi Cancer Clinic-Two RiversTwo Rivers, United StatesTaking people
Kaiser Permanente - Vallejo Medical CenterVallejo, United StatesTaking people
Florida Cancer Specialists South / Sarah Cannon Research InstituteVenice, United StatesNo longer taking part
Kaiser Permanente Walnut Creek Medical CenterWalnut Creek, United StatesTaking people
Henry Ford Health Warren HospitalWarren, United StatesTaking people
Aurora Cancer Care-Milwaukee WestWauwatosa, United StatesTaking people
York Hospital Oncology & Infusion Care in WellsWells, United StatesTaking people
West Chester HospitalWest Chester, United StatesTaking people
Windham Hospital (WH)Willimantic, United StatesTaking people
Florida Cancer Specialists North / Sarah Cannon Research InstituteWinter Park, United StatesNo longer taking part
York Hospital Oncology & Infusion Care in YorkYork Village, United StatesTaking people

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Print a page for my doctor

Trial details

Who runs it: American Society of Clinical Oncology
Trial code: NCT02693535
Record updated: 22 September 2026
Original description: The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact, or if a patient, your nearest participating TAPUR site (see participating centers). ******************************************************************** Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************Read full original descriptionShow less
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact, or if a patient, your nearest participating TAPUR site (see participating centers). ******************************************************************** Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. ********************************************************************
Inclusion: 12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18); Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication); Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria); Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:; Absolute neutrophil count ≥ 1500 µl; Hemoglobin ≥ 9.0 g/dl; Platelets ≥ 75,000/µl; Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome; Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases); Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2; Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma); Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above; Ability to understand and the willingness to sign a written informed consent/assent document; Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol; For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome; Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse; Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion: Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment; Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible; Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded; Patients with known progressive brain metastases are eligible but additional eligibility criteria apply; Note: there are additional exclusion criteria that may apply.
ClinicalTrials.gov NCT02693535